tunlametinib   Click here for help

GtoPdb Ligand ID: 11675

Synonyms: Example 9 [WO2013107283A1]
Compound class: Synthetic organic
Comment: We obtained the chemical structure for tunlametinib from WHO Proposed list 125 (July 2021). This mapped to PubChem CID 71621329. The chemical structure is claimed in Tianjin Binjiang Pharma's patent WO2013107283A1 for activity as a MEK inhibitor with potential to treat cancers and inflammation [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 111.72
Molecular weight 490.96
XLogP 3.82
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCCONC(=O)c1cc2scnc2c(c1Nc1ccc(cc1F)I)F
Isomeric SMILES Fc1c(c(cc2c1ncs2)C(=O)NOCCO)Nc1c(cc(cc1)I)F
InChI InChI=1S/C16H12F2IN3O3S/c17-10-5-8(19)1-2-11(10)21-14-9(16(24)22-25-4-3-23)6-12-15(13(14)18)20-7-26-12/h1-2,5-7,21,23H,3-4H2,(H,22,24)
InChI Key UFZJUVFSSINETF-UHFFFAOYSA-N
Bioactivity Comments
Tunlametinib (example 9) inhibits proliferation of HT29 and A375 cancer cell lines in vitro (IC50 ≤1 nM), and exhibits anti-tumour efficacy in an HT29 and COLO205 tumour xenograft models. No data for inhibition of MEK enzymatic activity is provided in WO2013107283A1 [1].